Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Showing 1779 results
January 2015
-
Media ReleaseNovartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patientsOffering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A[1],[2] Phase III data demonstrated Cosentyx…
-
Media ReleaseNovartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patientsCosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other…
-
Media ReleaseNovartis Pharmaceuticals announces a joint investment company with Qualcomm, leading innovation in digital medicines for physicians and patientsNovartis establishing a joint investment company with Qualcomm Ventures, the venture investment group of Qualcomm Incorporated, of up to USD 100 million to support early stage companies with…
-
Media ReleaseNovartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDAPivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung function in COPD patients[1-5] US trials for QVA149 demonstrated significant…
-
Media ReleaseSandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory CommitteeOncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested…
-
Media ReleaseNovartis collaborates with Intellia Therapeutics and Caribou Biosciences to explore making medicines and drug discovery tools with CRISPR genome editing technologyCollaborations give Novartis access to novel CRISPR technology platforms for the discovery and development of new medicines Intellia Therapeutics collaboration to explore therapeutic options for…
-
Story From Our Labs
Can we edit our genes to fight disease? -
Story From Our Labs
Rebuilding bloodWhy are some sickle cell disease patients protected from the disease? Learn about our biomedical research in the field.
December 2014
-
Story Access to Healthcare
Talking to: Juergen Brokatzky-Geiger, Global Head of Corporate Responsibility at NovartisIn October 2013, we created a new, full-time position to lead our CR efforts. Juergen Brokatzky-Geiger, formerly Global Head of Human Resources and a member of the Executive Committee, took on this role effective in February 2014.
-
Story Discovery
A fresh look at fighting glaucomaAsk Alan Frohman how he found out that he had glaucoma, and he'll quickly tell you that there were no warning signs.
